knowledge -WSS

knowledge

author：Wikipedia 2025-09-28 22:53:23 - browse：42914

President of Bayer U.S. Sebastian Guth speaks with STAT reporters at STAT's Boston headquarters, March 13, 2024 — Bayer's U.S. president, Sebastian Guth, emphasized at an interview at the STAT offices in Boston that the pharma company is no longer just focused on small molecules. Alissa Ambrose/STAT

German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and pricing pressures that have led many in the drug industry to bemoan the potential end of the American biotech innovation boom.

Bayer’s C-suite has been on a soul-searching mission for the last year, spurred by new leadership and the realization that the company is, as new CEO Bill Anderson said earlier this month, “badly broken.”

The biggest fissure is the debt and litigation costs stemming from Bayers’s 2018 acquisition of agriculture firm Monsanto, but the aspirin-maker’s pharmaceutical portfolio is also facing strain. Some of Bayer’s top products, including the anticoagulant drug Xarelto and the eye medication Eylea, are under patent pressure. Xarelto is also one of the first drugs to be subject to Medicare price negotiations under the Inflation Reduction Act, though Johnson & Johnson owns U.S. rights to the drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Senate panel clears PBM, hopsital reforms

hotspot

leisure time

WSS

Fentanyl is making it harder to start addiction treatment

Study: New antibiotic targets gonorrhea as well as last existing drug

Ambulance rides for just $100? Advisers want major billing fixes

Medicare solvency divides Republicans at the presidential debate

Bird flu surveillance in wastewater gets boost from consortium

Diversify hospital leadership teams to protect BIPOC patient health

focus

knowledge

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Tori Bowie and the unacceptable rates of Black maternal death

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Walensky prepares to leave CDC — and Congress — behind

H5N1 virus can be tracked in retail milk, scientists say

FDA approval of Sarepta Duchenne genetic therapy gives me hope

H5N1 virus can be tracked in retail milk, scientists say

Guidelines to prevent youth baseball injuries need more muscle

Listen: A conversation with researcher Kevin Esvelt on biosecurity

hotspot

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Biogen joins immunology wave with $1.15 billion acquisition of HI

Fentanyl is making it harder to start addiction treatment

Bird flu surveillance in wastewater gets boost from consortium

Fentanyl is making it harder to start addiction treatment

FDA poised to publish guidelines for clinical trial diversity

hotspot

focus

leisure time

leisure time